Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

McQuellon, Richard P.; Danhauer, Suzanne C.; Russell, Gregory B.; Shen, Perry; Fenstermaker, Joyce; Stewart, John H.; Levine, Edward A.

doi:10.1245/s10434-006-9304-5

Cited by 60 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The surgery is presumed to have a lasting negative impact on the patients quality of life. While there have been no studies that look at patients undergoing CRS and HIPEC for gastric cancer in particular, there have been numerous retrospective and prospective studies that have looked at patients undergoing CRS and HIPEC for various pathologies [69][70][71][72][73][74][75][76]. Various quality of life instruments have been used which include the EORTC and SF 21.…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Chia

Seshadri

Képénékian³

et al. 2016

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: The current treatment of choice for peritoneal carcinomatosis from gastric cancer is systemic chemotherapy. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a new aggressive form of loco-regional treatment that is currently being used in pseudomyxoma peritoneii, peritoneal mesothelioma and peritoneal carcinomatosis from colorectal cancer. It is still under investigation for its use in gastric cancer. Methods: The literature between 1970 and 2016 was surveyed systematically through a review of published studies on the treatment outcomes of CRS and HIPEC for peritoneal carcinomatosis from gastric cancer. Results: Seventeen studies were included in this review. The median survival for all patients ranged from 6.6 to 15.8 months. The 5-years overall survival ranged from 6 to 31%. For patients with complete cytoreduction, the median survival was 11.2 to 43.4 months and the 5-years overall survival was 13 % to 23%. Important prognostic factors were found to be a low peritoneal carcarcinomatosis index (PCI) score and the completeness of cytoreduction.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Chia

Seshadri

Képénékian³

et al. 2016

Pleura and Peritoneum

View full text Add to dashboard Cite

show abstract

“…Les critères de jugement àc onsidérer sont dans ce cas la qualité de vie, la survie sans symptôme et la survie sans hospitalisation. Une étude prospective [13] [92]. Finalement, il faut insister sur le fait que la majorité des études d'évaluation de la CIP ou de la CHIP ont été réalisées en Asie.…”

Section: ❚ Place De La Chirurgie Palliativeunclassified

Cancer de l’estomac : prise en charge chirurgicale

Briez¹,

Dupré²,

Piessen³

et al. 2011

Cancérodig.

View full text Add to dashboard Cite

“…The largest number of patients analyzed and ever published with respect to QoL included 96 patients [26]. These patients completed a questionnaire before and after surgery at 3, 6, and 12 months (basically FACT-C, SF-36, and CES-D).…”

Section: Journal Of Surgical Oncologymentioning

confidence: 99%

Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Piso¹,

Glockzin²,

Breitenbuch³

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6-12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC.

show abstract

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

Abstract: Acceptable QOL, return of functional status, and reduced pain can be attained between 3 and 6 months following treatment although some deficits in general health remain. Depressive symptoms are common and should be monitored.

Cited by 60 publications

References 15 publications

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Cancer de l’estomac : prise en charge chirurgicale

Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Contact Info

Product

Resources

About